Hellman K, Ohlsson J, Malo M, Olsson R, Ek F. Discovery of Procognitive Antipsychotics by Combining Muscarinic M1 Receptor Structure-Activity Relationship with Systems Response Profiles in Zebrafish Larvae. ACS Chem Neurosci. 2020;11:173-183 pubmed publisher

Choi H, Im S, Park H, Park S, Kim C, Ryu S. Long-term Effects of Aripiprazole Treatment during Adolescence on Cognitive Function and Dopamine D2 Receptor Expression in Neurodevelopmentally Normal Rats. Clin Psychopharmacol Neurosci. 2019;17:400-408 pubmed publisher

Johnston A, Bu W, Hein S, Garcia S, Camacho L, Xue L, et al. Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. Breast Cancer Res. 2018;20:42 pubmed publisher

Deiana S, Watanabe A, Yamasaki Y, Amada N, Kikuchi T, Stott C, et al. MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol. Behav Pharmacol. 2015;26:748-65 pubmed publisher

Johansen L, Dewald L, Shoemaker C, Hoffstrom B, Lear Rooney C, Stossel A, et al. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. Sci Transl Med. 2015;7:290ra89 pubmed publisher

Moezi L, Hosseini M, Oveisi S, Niknahad H, Shafaroodi H. The Effects of Sub-Chronic Treatment with Aripiprazole on Pentylenetetrazole- and Electroshock-Induced Seizures in Mice: The Role of Nitric Oxide. Pharmacology. 2015;95:264-70 pubmed publisher

Uchida S, Hiraoka S, Namiki N. Development of gummi drugs of aripiprazole as hospital formulations. Chem Pharm Bull (Tokyo). 2015;63:354-60 pubmed publisher

Rodday A, Parsons S, Mankiw C, Correll C, Robb A, Zima B, et al. Child and adolescent psychiatrists' reported monitoring behaviors for second-generation antipsychotics. J Child Adolesc Psychopharmacol. 2015;25:351-61 pubmed publisher

Baba S, Enomoto T, Horisawa T, Hashimoto T, Ono M. Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range. J Pharmacol Sci. 2015;127:326-31 pubmed publisher

Kishi T, Matsuda Y, Mukai T, Matsunaga S, Yasue I, Fujita K, et al. A cross-sectional survey to investigate the prevalence of pain in Japanese patients with major depressive disorder and schizophrenia. Compr Psychiatry. 2015;59:91-7 pubmed publisher

Srisurapanont M, Suttajit S, Maneeton N, Maneeton B. Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. J Psychiatr Res. 2015;62:38-47 pubmed publisher

Deng C, Pan B, Hu C, Han M, Huang X. Differential effects of short- and long-term antipsychotic treatment on the expression of neuregulin-1 and ErbB4 receptors in the rat brain. Psychiatry Res. 2015;225:347-54 pubmed publisher

Brust T, Hayes M, Roman D, Burris K, Watts V. Bias analyses of preclinical and clinical D2 dopamine ligands: studies with immediate and complex signaling pathways. J Pharmacol Exp Ther. 2015;352:480-93 pubmed publisher

Suzuki K, Harada A, Shiraishi E, Kimura H. In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents. J Pharmacol Exp Ther. 2015;352:471-9 pubmed publisher

Oosterhof C, El Mansari M, Blier P. Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization. J Pharmacol Exp Ther. 2014;351:585-95 pubmed publisher

Bayliss P, Holttum S. Experiences of antidepressant medication and cognitive-behavioural therapy for depression: a grounded theory study. Psychol Psychother. 2015;88:317-34 pubmed publisher

Patteet L, Maudens K, Stove C, Lambert W, Morrens M, Sabbe B, et al. The use of dried blood spots for quantification of 15 antipsychotics and 7 metabolites with ultra-high performance liquid chromatography - tandem mass spectrometry. Drug Test Anal. 2015;7:502-11 pubmed publisher

Papp M, Gruca P, Lasoń Tyburkiewicz M, Adham N, Kiss B, Gyertyán I. Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. Behav Pharmacol. 2014;25:567-74 pubmed publisher

Shishikura M, Hakariya H, Iwasa S, Yoshio T, Ichiba H, Yorita K, et al. Evaluation of human D-amino acid oxidase inhibition by anti-psychotic drugs in vitro. Biosci Trends. 2014;8:149-54 pubmed

Maeda K, Lerdrup L, Sugino H, Akazawa H, Amada N, McQuade R, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350:605-14 pubmed publisher

Nagasaka Y, Sano T, Oda K, Kawamura A, Usui T. Impact of genetic deficiencies of P-glycoprotein and breast cancer resistance protein on pharmacokinetics of aripiprazole and dehydroaripiprazole. Xenobiotica. 2014;44:926-32 pubmed publisher

Paquette S, Dawit H, Hickey M, Merisko Liversidge E, Almarsson O, Deaver D. Long-acting atypical antipsychotics: characterization of the local tissue response. Pharm Res. 2014;31:2065-77 pubmed publisher

Lofwall M, Nuzzo P, Campbell C, Walsh S. Aripiprazole effects on self-administration and pharmacodynamics of intravenous cocaine and cigarette smoking in humans. Exp Clin Psychopharmacol. 2014;22:238-47 pubmed publisher

Ye N, Song Z, Zhang A. Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents. Curr Med Chem. 2014;21:437-57 pubmed

Richtand N, Ahlbrand R, Horn P, Tambyraja R, Grainger M, Bronson S, et al. Fluoxetine and aripiprazole treatment following prenatal immune activation exert longstanding effects on rat locomotor response. Physiol Behav. 2012;106:171-7 pubmed publisher

Taylor D. Aripiprazole: a review of its pharmacology and clinical use. Int J Clin Pract. 2003;57:49-54 pubmed